Omalizumab for Peanut Allergy
(OUtMATCH Trial)
Recruiting in Palo Alto (17 mi)
+9 other locations
Age: < 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Pivotal Trial (Near Approval)
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew, hazelnut, or walnut). While each participant may be allergic to more than two other foods, the primary endpoint/outcome in this study will only be assessed in peanut and two other foods for each participant. The primary objective of the study is to compare the ability to consume foods without dose-limiting symptoms during a double-blind placebo-controlled food challenge (DBPCFC), after treatment with either omalizumab or placebo for omalizumab.
Eligibility Criteria
This trial is for people aged 1-55 with peanut and at least two other specific food allergies (milk, egg, wheat, cashew, hazelnut, walnut). They must have a positive skin test and immunoglobulin E levels for these allergens. Participants should be near the research unit during the study and trained to use an epinephrine autoinjector. Women of childbearing age must not be pregnant or breastfeeding and agree to use contraception.Inclusion Criteria
Positive SPT (≥4 mm wheal) to food
Plan to remain in the study area of an OUtMATCH clinical research unit (CRU) during the trial
You have allergies to at least two out of six specific foods (milk, egg, wheat, cashew, hazelnut, walnut). This is to ensure that participants are likely to maintain their allergies throughout the study and not develop tolerance to these foods.
+16 more
Exclusion Criteria
Has a first-degree relative already enrolled in the study
You have conditions or factors that could affect the accuracy or understanding of the study results.
Current participation in another therapeutic or interventional clinical trial or participation within 90 days of Screening
+27 more
Participant Groups
The study tests if omalizumab can help participants consume foods without symptoms compared to a placebo. It's randomized and double-blind: neither doctors nor patients know who gets real treatment or placebo. The focus is on tolerating peanuts and two other allergens after treatment.
7Treatment groups
Experimental Treatment
Placebo Group
Group I: Stage 3: DBPCFC Based TreatmentExperimental Treatment1 Intervention
DBPCFC Based Treatment-Long-term Follow-up Treatment Plan for Peanut and Each of the Two Other Participant-Specific Foods.
Upon completion of the DBPCFCs at the end of Stage 1 OLE or Stage 2, each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods based on the results of the DBPCFCs. A treatment plan will include instructions for one of the following:
* Long-term follow-up with dietary consumption of a food;
* Long-term follow-up with avoidance of a food; or
* Rescue OIT for a food.
The treatment plan for each food may change throughout Stage 3 depending on a participant's response to treatment. Once a participant enters Stage 3, the participant will have a minimum of 12 months follow-up until at least December 2022.
Note: Participants will be instructed to strictly avoid a food if they receive rescue OIT for the food during Stage 3.
Group II: Stage 2: Omalizumab-Facilitated OITExperimental Treatment2 Interventions
OIT: oral immunotherapy-Omalizumab as Adjunct Therapy to Multi-Allergen Oral Immunotherapy
Participants randomized to open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks.
Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic.
Group III: Stage 2: Omalizumab + Placebo OITExperimental Treatment2 Interventions
OIT: oral immunotherapy Participants randomized to open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.
Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic.
Group IV: Stage 2: OmalizumabExperimental Treatment1 Intervention
Participants will receive eight weeks of treatment with open label omalizumab in accordance with the omalizumab dosing table specified in the study protocol, administered by subcutaneous injection. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
After completion of eight weeks of open label omalizumab, participants will be randomized 1:1 to either:
* Omalizumab-facilitated oral immunotherapy (OIT): Open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks OR
* Omalizumab + placebo OIT: Open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.
Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic.
Group V: Stage 1:Omalizumab as MonotherapyExperimental Treatment1 Intervention
Eligible participants are randomized to receive omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
After 16 weeks of treatment, each participant will complete double-blind placebo-controlled food challenge (DBPCFCs) to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.
Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.
The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 Open Label Extension (OLE).All other participants who complete all four DBPCFCs will move Stage 2 of the study.
Group VI: Stage 1: Omalizumab OLEExperimental Treatment1 Intervention
OLE: Open Label Extension, Long-Term Treatment with Omalizumab. Participants will receive 24 weeks of open label omalizumab in accordance with the omalizumab dosing table defined in the study protocol. Omalizumab is administered by subcutaneous injection either every 2 weeks or every 4 weeks for 24 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
After 24 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 8044 mg protein of each food. Each participant who completes all four DBPCFCs at the end of the Stage 1 OLE will move on to Stage 3 of the study.
Throughout Stage 1 OLE, each participant will be instructed to strictly avoid all foods to which they are allergic.
Group VII: Stage 1: Placebo for Omalizumab as MonotherapyPlacebo Group1 Intervention
Eligible participants are randomized to receive placebo for omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
After 16 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.
Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.
The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 OLE. All other participants who complete all four DBPCFCs will move Stage 2 of the study.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
National Jewish Health: Division of Pediatric Allergy and Clinical ImmunologyDenver, CO
Emory University School of Medicine: Children's Healthcare of Atlanta PediatricsAtlanta, GA
Massachusetts General Hospital, Department of Medicine: Allergy & Clinical Immunology UnitBoston, MA
North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and RheumatologyChapel Hill, NC
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor
Rho Federal Systems Division, Inc.Industry Sponsor
Novartis PharmaceuticalsIndustry Sponsor
Genentech, Inc.Industry Sponsor